Belimumab (subcutaneous injection) add-on for systemic lupus erythematosus in children aged 5 to 17 years old

Belimumab (subcutaneous injection) is currently in clinical development as an add-on therapy for active systemic lupus erythematosus (SLE) in patients aged 5 to 17 years old. SLE is an autoimmune disease where the body’s immune system attacks its own tissues and organs. Patients will often have periods where their symptoms flare-up and periods where their symptoms settle down. In children, SLE is more severe than in adults. Currently, conventional SLE treatments, such as corticosteroids and immunosuppressants, are known to have issues with efficacy and long-term toxicity.